Benzinga
Benzinga
Benzinga
viernes, septiembre 11

X4 Pharmaceuticals Inc

XFORNASDAQ
Trade with Public
Trade with Public
$3.40
-0.20-5.56%
al cierre: Sep 9, 5:00 PM EST
$3.42
-0.18-5%
Premercado: 4:00 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

X4 Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for X4 Pharmaceuticals (XFOR).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$13Upside to Avg. PT+271.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Jul 10, 2026Wells FargoDerek ArchilaInitiateOverweight$11
Jun 2, 2026Leerink PartnersThomas SmithInitiateOutperform$12
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $3.5 to $5.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved